-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PsdwUb6YW7g15BSEMzjag6DGp4YKWHWURP4eWaRxTFNA/aE4Vm9UP1a5O7SAYMkJ ozBcORF8NoAOm3Jw00nTXg== 0000950103-98-000368.txt : 19980408 0000950103-98-000368.hdr.sgml : 19980408 ACCESSION NUMBER: 0000950103-98-000368 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980407 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PROTEIN DESIGN LABS INC/DE CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-43256 FILM NUMBER: 98588631 BUSINESS ADDRESS: STREET 1: 2375 GARCIA AVE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 4159033700 MAIL ADDRESS: STREET 1: 2375 GARCIA AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CORANGE INTERNATIONAL LTD CENTRAL INDEX KEY: 0000935658 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: CHURCH AND PARLIAMENT CITY: HAMILTON STATE: D0 ZIP: 00000 BUSINESS PHONE: 3175763950 MAIL ADDRESS: STREET 1: C/O BOCHRIGER MANCHISM CORP STREET 2: 9115 HAGUE ROAD CITY: INDIANAPOLIS STATE: IN ZIP: 46250 SC 13G 1 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION STATEMENT PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) PROTEIN DESIGN LABS, INC. (Name of Issuer) COMMON STOCK $.01 PAR VALUE (Title of Class of Securities) 74369L 103 (CUSIP Number) March 5, 1998 (Date of Event Which Requires Filing of this Statement) Check the box to designate the rules pursuant to which this Schedule is filed [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) ================================================================================ CUSIP No.15115610 13G Page ___ of 6 Pages - ----------------- ---------------------------- 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Corange International Limited 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Bermuda NUMBER OF SHARES 5 SOLE VOTING POWER BENEFICIALLY OWNED BY 1,682,877 EACH REPORTING PERSON WITH 6 SHARED VOTING POWER -0- 7 SOLE DISPOSITIVE POWER 1,682,877 8 SHARED DISPOSITIVE POWER 0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,682,877 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.17% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTIONS BEFORE FILLING OUT! Item 1(a). Name of Issuer. Protein Design Labs, Inc. (the "Company"). Item 1(b). Address of Issuer's Principal Executive Offices. 2375 Garcia Avenue Mountain View, CA 94043 Item 2(a). Name of Person Filing. This Schedule 13G amends Amendment No. 2 to Schedule 13D filed on April 4, 1997 by Corange International Limited ("CIL") in respect of shares of Common Stock of the Company. On March 5, 1998, Roche Healthcare Limited, a Bermuda corporation ("Purchaser"), consummated its acquisition (the "Acquisition") of all of the outstanding capital stock of Corange Limited ("Corange"). At the time of the Acquisition, Corange owned, through its wholly-owned subsidiary CIL, 1,682,877 shares of Common Stock of the Company. Corange is a Bermuda corporation. CIL, a Bermuda corporation, is a subsidiary of Corange. Purchaser is a wholly owned subsidiary of Roche Finance Ltd, a Swiss corporation ("Finance"), which, in turn, is a wholly owned subsidiary of Roche Holding Ltd, a Swiss corporation ("Holding"). Dr. h.c. Paul Sacher, an individual and citizen of Switzerland ("Dr. Sacher") has, pursuant to an agreement, the power to vote a majority of the voting securities of Holding. Item 2(b). Address of Principal Business Office or, if None, Residence. The address of the principal offices of Purchaser and CIL is Church & Parliament Sts., Hamilton, HM 12, Bermuda. The address of the principal offices of Finance is Grenzacherstrasse 122, Basel, Switzerland. The address of the principal offices of Holding is Grenzacherstrasse 124, Basel 4002, Switzerland. The business address of Dr. Sacher is Haus auf Burg, Muensterplatz 4, Basel 4051, Switzerland. Item 2(c). Citizenship. See Item 2(b). Item 2(d). Title of Class of Securities. This statement relates to the Company's common stock, par value $0.01 per share (the "Common Stock"). Item 2(e). CUSIP Number. 74369L 103 Item 3. If this statement is filed pursuant to Rule 13d-1(b) or (c), or 13d-2(b), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Exchange Act, (b) [ ] Bank as defined in Section 3(a)(6) of the Exchange Act, (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Exchange Act, (d) [ ] Investment Company registered under Section 8 of the Investment Company Act, (e) [ ] Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E), (f) [ ] Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F), (g) [ ] Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G), (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act, (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act, (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). If this statement is filed pursuant to Rule 13d-1(c), check this box. [X] Item 4. Ownership. (a) Amount beneficially owned: 1,682,877 shares of Common Stock (b) Percent of class: 9.17% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 1,682,877 (ii) Shared power to vote or to direct the vote: -0- (iii) Sole power to dispose or to direct the disposition of: 1,682,877 (iv) Shared power to dispose or to direct the disposition of: -0- Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [ ] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: April 3, 1998 CORANGE INTERNATIONAL LIMITED By: /s/ Graham B.R. Collis ---------------------- Name: Graham B.R. Collis Title: Director Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). -----END PRIVACY-ENHANCED MESSAGE-----